HONG KONG – Daejeon, South Korea-based biotechnology company G2GBIO Inc. has raised ₩11.4 billion (US$9.53 million) from a series B financing round, with the funds to be used on clinical trials for a sustained-release Alzheimer’s treatment as well as nonclinical trials for diabetes and sustained-release postoperative pain treatments.
By deleting the gene for uridine monophosphate synthetase (UMPS), an enzyme in the pathway for uridine synthesis, researchers have made cells, including embryonic stem cells and T cells, dependent on dietary uridine. The work, which was published in the July 13, 2020, online issue of Nature Biotechnology, adds a new potential way of controlling cell therapies.
By deleting the gene for uridine monophosphate synthetase (UMPS), an enzyme in the pathway for uridine synthesis, researchers have made cells, including embryonic stem cells and T cells, dependent on dietary uridine. The work, which was published in the July 13, 2020, online issue of Nature Biotechnology, adds a new potential way of controlling cell therapies.
HONG KONG – Daejeon, South Korea-based biotechnology company G2GBIO Inc. has raised ₩11.4 billion (US$9.53 million) from a series B financing round, with the funds to be used on clinical trials for a sustained-release Alzheimer’s treatment as well as nonclinical trials for diabetes and sustained-release postoperative pain treatments.
The first bispecific antibody to win regulatory approval, Removab (catumaxomab) was voluntarily withdrawn due to commercial reasons. Now Chinese biotech Lintonpharm Co. Ltd., of Guangzhou, said it plans to move catumaxomab to a global phase III trial following an IND approval from China’s NMPA, investigating the trifunctional bispecific antibody in patients with peritoneal carcinomatosis, a form of advanced gastric cancer.
PERTH, Australia – With a series A investment in hand, Glyscend Therapeutics Inc. will take its polymer therapeutic that mimics the effect of gastric bypass surgery to Australia next year to begin clinical trials.
The first bispecific antibody to win regulatory approval, Removab (catumaxomab) was voluntarily withdrawn due to commercial reasons. Now Chinese biotech Lintonpharm Co. Ltd., of Guangzhou, said it plans to move catumaxomab to a global phase III trial following an IND approval from China’s NMPA, investigating the trifunctional bispecific antibody in patients with peritoneal carcinomatosis, a form of advanced gastric cancer.
PERTH, Australia – With a series A investment in hand, Glyscend Therapeutics Inc. will take its polymer therapeutic that mimics the effect of gastric bypass surgery to Australia next year to begin clinical trials.
Endpoint Health Inc. has made its official debut, scooping up $12 million in debt and equity financing from a host of investors, including Mayfield, Y Combinator, Ame Cloud Ventures and Wireframe Ventures. The Palo Alto, Calif.-based company is focused on helping people with illnesses such as sepsis and acute respiratory distress syndrome (ARDS) – life-threatening conditions often caused by serious infections, including COVID-19.
Armed with intellectual property generated in the lab of Edgar Engleman at Stanford University, Tranquis Therapeutics Inc. has emerged from stealth mode through a $30 million series A round.
RSS
